Drug Profile
Research programme: ALK1 kinase inhibitors - Oncodesign
Alternative Names: ALK1 inhibitors - OncodesignLatest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Oncodesign Biotechnology
- Class Antineoplastics; Macrocyclic compounds
- Mechanism of Action ACVRL1 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer